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Angiotensin-converting enzyme inhibitors and angiotensin II
type I receptor blockers delay progression of chronic kidney
disease and have antiproteinuric effects beyond their effects
on blood pressure. They are routinely used in adults;
however, their efficacy and safety in children, in whom the
causes of chronic kidney disease are significantly different
relative to adults, is uncertain. Here we assessed an open-
label extension of a previous 3-month blinded trial, in which
the efficacy and tolerability of losartan was compared to
placebo or amlodipine in 306 normotensive and
hypertensive children with proteinuria. In this study, 268
children were re-randomized to losartan or enalapril and
followed until 100 patients completed 3 years of follow-up
for proteinuria and renal function. The least squares percent
mean reduction from baseline in the urinary protein/
creatinine ratio was 30.01% for losartan and 40.45% for
enalapril. The least squares mean change from baseline in
eGFR was 3.3ml/min per 1.73m2 for losartan and 7.0ml/min
per 1.73m2 for enalapril. The incidence of specific adverse
events such as hyperkalemia and renal dysfunction was low
and similar in both groups. Both were generally well
tolerated and, overall, fewer drug-related adverse events
occurred with losartan than with enalapril. Thus, in children
with proteinuria, losartan and enalapril significantly reduced
proteinuria without any appreciable changes in eGFR, effects
that were maintained throughout the study. Both losartan
and enalapril were generally well tolerated.
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The prevalence of significant proteinuria (41g/day) in
children with chronic kidney disease (CKD) ranges from
5.8% in stage 1 to 40% in stage 5 CKD,1 and lower level
proteinuria is even more prevalent. Persistent proteinuria is
viewed as being directly injurious to the kidneys,2,3 and may
be a long-term risk factor for atherosclerosis.4,5 In adults with
diabetic and non-diabetic CKD, angiotensin-converting
enzyme inhibitors (ACE-Is) and angiotensin II type I
receptor blockers (ARBs) delay progression to stage 5 CKD
and have antiproteinuric effects distinct from their effects on
blood pressure (BP).6–12 These agents are routinely used in
adults; however, there remains uncertainty about their
efficacy and safety in children, in whom the causes of CKD
are significantly different relative to adults. In children
treated with ramipril in the ESCAPE study, proteinuria was
initially reduced; however, it returned to near baseline levels
after 36–42 months of therapy.13
We have recently reported the results of a 12-week,
randomized, double-blind, controlled trial that showed that
pharmacological blockade of the renin–angiotensin system
(RAS) with losartan safely and effectively reduced proteinuria
in normotensive and hypertensive children (N¼ 306) aged
1–17 years.14 This manuscript describes the open-label
extension phase of this study, in which long-term efficacy
and tolerability of losartan vs. enalapril after 3 years of
treatment were assessed.
RESULTS
Patient population
Of the 306 patients in the 12-week double-blind study, 268
(87.6%) entered the open-label extension phase and were re-
randomized to receive either losartan (N¼ 134) or enalapril
(N¼ 134). Of these, 109 patients (55 on losartan and 54 on
enalapril) completed 3 years of follow-up before the study
ended; a further 92 patients remained until study termina-
tion, but had o3 years of open-label treatment; 67 patients
discontinued for other reasons, including 11 in the losartan
group and eight in the enalapril group who discontinued
because of an adverse event (AE). There were no clinically
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meaningful differences between the two treatment groups in
the percentages of patients completing the study, discontinu-
ing because of study termination, or discontinuing for other
reasons. The actual average dosage rates were 1.17 for
losartan and 0.26mg/kg/day for enalapril. Additional ACE-Is
and ARBs were discouraged.
Baseline characteristics were generally similar between the
two treatment groups (Table 1). The mean age was 10.1 years.
Similar to the distribution in the 12-week double-blind study,
480% of the patients were normotensive. There were
numerical differences between treatment groups in baseline
values for urinary protein/creatinine ratio (UPr/Cr) that were
not confirmed statistically, and no notable differences
between treatment groups in baseline values for estimated
glomerular filtration rate (eGFR), cystatin-C, sitting systolic
BP, and sitting diastolic BP (with corresponding age-/
gender-/height-adjusted percentiles).
Proteinuria
After 3 years of treatment, the estimated least squares (LS)
mean reduction from baseline in UPr/Cr was 30.01% on
losartan vs. 40.45% on enalapril (Figure 1a). The estimated
ratio of geometric means (GMR) (95% confidence interval
(CI)) was 1.18% (0.86, 1.60). Proteinuria reduction was
consistently observed in normotensive and hypertensive
cohorts (Figure 1b and c), after adjusting for time-varying
changes in BP and across all prespecified subgroups, including
age, gender, race, Tanner stage, weight, prior therapy with
ACE-Is/ARBs, and prior treatment assignment in the base
phase (losartan, amlodipine/placebo) (data not shown).
As NSAIDs, systemic corticosteroids, and immunosup-
pressants may produce substantial effects on proteinuria, a
sensitivity analysis was performed, excluding data from
patients within 2 weeks of taking NSAIDs and after starting
systemic corticosteroids or other immunosuppressants if they
had taken these medications for at least 50% of their
remaining time in the study. After excluding complete data
from 51 (and partial data from 17) patients, the LS mean
reduction from baseline in UPr/Cr was 26.50% with losartan
vs. 28.24% with enalapril (GMR: 1.02; 95% CI: 0.78, 1.34).
Estimated glomerular filtration rate
After 3 years of treatment, the estimated LS mean change
from baseline in eGFR was 3.3ml/min per 1.73m2 on
losartan vs. 7.0ml/min per 1.73m2 on enalapril (Figure 2a).
LS mean treatment difference was 3.8ml/min per 1.73m2
(95% CI: 15.2, 7.6). Changes from baseline in eGFR were
consistently observed in normotensive and hypertensive
cohorts (Figure 2b and c) and after adjusting for time-
varying changes in BP and after excluding data observed
following the use of concomitant NSAIDs, systemic corti-
costeroids, or other immunosuppressants, and across all
prespecified subgroups (data not shown). A supportive
analysis performed for the change from baseline after 3 years
of treatment in eGFR, adjusting the model for baseline
urinary protein excretion demonstrated that the estimated LS
mean change from baseline in eGFR was 4.6ml/min per
1.73m2 on losartan vs. 7.0ml/min per 1.73m2 on enalapril,
consistent with the results of the main analyses.
Cystatin C
Small mean decreases in cystatin C were observed at all time
points in the enalapril group; however, there was no
consistent pattern of change at any time point in the losartan
group (Figure 3).
Table 1 | Baseline characteristics
Characteristic
Losartan,
N=134
Enalapril,
N=134
Age, years; mean (s.d.) 9.8 (4.8) 10.4 (4.7)
Range 1.0–18.0 1.0–17.0
o6 (%) 35 (26.1) 32 (23.9)
7–12 (%) 50 (37.3) 48 (35.8)
13–17 (%) 48 (35.8) 54 (40.3)
X18 (%) 1 (0.7) 0 (0.0)
Gender; n (%)
Male 86 (64.2) 72 (53.7)
Female 48 (35.8) 62 (46.3)
Race; n (%)
Asian 24 (17.9) 19 (14.2)
Black 6 (4.5) 2 (1.5)
Multiracial 27 (20.1) 41 (30.6)
White 70 (52.2) 68 (50.7)
Other 7 (5.2) 4 (3.0)
Tanner stage; n (%)
I–III 106 (79.1) 95 (70.9)
IV–V 28 (20.9) 39 (29.1)
Prior ACE-I/ARB use; n (%)
Yes 71 (53.0) 76 (56.7)
No 63 (47.0) 58 (43.3)
Body mass index, kg/m2; mean (s.d.);
range
19.4 (5.8);
11.7–56.2
19.3 (3.7);
12.4–29.2
Duration of hypertensiona, years;
mean (s.d.); range
4.8 (4.2);
2.0–16.0
6.4 (4.6);
1.0–17.0
Urinary protein/creatinine ratio,
mg/mmol; mean (s.d.); range
310 (490);
10–2980
220 (350);
10–2680
Urinary protein/creatinine ratio,
mg/mmol; median
130 90
Estimated glomerular filtration rate,
ml/min per 1.73 m2; mean (s.d.); range
116.5 (51.3);
26.9–280.5
119.0 (51.8);
14.9–301.1
Cystatin-C, nmol/l; mean (s.d.); range 895.4
(466.6);
375.0–2475.0
914.9
(636.6);
375.0–4350.0
Sitting systolic blood pressure,
mmHg; mean (s.d.)
103.6 (14.0) 104.1 (14.1)
Age/gender/height-adjusted percentile 56.1 (29.9) 53.3 (29.3)
Sitting diastolic blood pressure,
mmHg; mean (s.d.)
65.2 (11.1) 65.3 (11.7)
Age/gender/height-adjusted
percentile
66.4 (25.3) 63.8 (25.5)
Treatment in base study; n (%)
Losartan 67 (50.0) 67 (50.0)
Placebo 54 (40.3) 55 (41.0)
Amlodipine 13 (9.7) 12 (9.0)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AE, adverse event;
ARB, angiotensin II type I receptor blocker.
aCalculated for patients in the hypertensive stratum (losartan, n=26; enalapril, n=25).
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Safety
The mean duration of treatment during the open-label
extension phase was similar between the two treatment
groups: 909 days for losartan and 903 days for enalapril.
Clinical AEs were experienced by 82.1% of patients on
losartan and 75.4% of patients on enalapril. The most
common AEs in both treatment groups and in the
hypertensive/normotensive groups were nasopharyngitis
and pharyngitis (Table 2). The numbers of patients with
serious clinical AEs and patients who discontinued due to an
AE were similar between the treatment groups. Drug-related
AEs occurred less frequently in the losartan treatment group
than in the enalapril group. Two drug-related serious AEs
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Figure 1 |Change (%) from baseline in urine protein excretion
over 36-month follow-up period. (a) Entire study population, (b)
normotensive subjects, (c) and hypertensive subjects. CI,
confidence interval; UPr/Cr, urinary protein/creatinine ratio.
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Figure 2 |Change (ml/min per 1.73m2) from baseline in
estimated glomerular filtration rate over 36-month follow-up
period. (a) Entire study population, (b) normotensive subjects, (c)
and hypertensive subjects. eGFR, estimated glomerular filtration
rate; LS, least squares.
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(1.5%) occurred on losartan: one event of acute renal failure
in the setting of severe dehydration; and one of ‘renal
impairment’ on concomitant treatment with (non-study
drug) enalapril resulting in discontinuation. Six deaths were
reported during the extension: three in the losartan group
(sepsis in a patient with acute lymphoblastic leukemia; acute
renal failure in a patient with steroid-resistant nephrotic
syndrome and progressive deterioration of renal function;
and complications of systemic lupus erythematosus in one
patient); and three in the enalapril group (all from
complications of systemic lupus erythematosus).
No cases of angioedema were reported. The incidences of
renal dysfunction, hypotension, and hyperkalemia were low
(Table 2). Renal dysfunction occurred at comparable rates with
losartan and enalapril. Four symptomatic cases of hypotension
were reported for losartan (three in normotensive patients and
one in a hypertensive patient) and none for enalapril: three were
deemed unrelated to losartan by the local principal investigator;
two of the events involved concomitant administration of ACE-
Is (as non-study drugs), one of which was considered related to
the ACE-I. Hyperkalemia was the most frequent drug-related
AE and was more common on enalapril (Table 2). Two of the
four hyperkalemia events on losartan (three in normotensive
patients and one in a hypertensive patient) and six of the nine
on enalapril (six in normotensive patients and three in
hypertensive patients) were increases in serum potassium of
41.0mmol/l; one patient on losartan and three on enalapril
had values 46.5mmol/l (one patient on enalapril had an
increase of 2.8mmol/l in the setting of renal failure, for which
study drug was discontinued). No patients with hyperkalemia
were receiving both an ACE-I and an ARB concomitantly.
There were no clinically significant differences between the
treatment groups in predefined limits of change (PDLC).
Increase in serum potassium was the most frequently
observed PDLC; 49 (38.9%) patients on losartan (8, 23,
and 18 had mean increases ofo0.6, 0.6–1.0, and41mmol/l,
respectively; the majority of those 41mmol/l were
o1.5mmol/l, although one event was an increase of
2.8mmol/l). For patients on enalapril, 54 (42.5%) (5, 26,
and 23 had increases of o0.6, 0.6–1.0, and 41mmol/l,
respectively, the majority of those 41mmol/l were
o1.5mmol/l, although six patients had increases of
42.0mmol/l). Serum creatinine increases were common,
including 43 (33.9%) on losartan (19, 12, and 12 patients had
increases of o44.2, 444.2–88.4, and 488.4 mmol/l, respec-
tively) and 31 (24.4%) on enalapril (12, 10, and 9 patients
had increases of o44.2, 444.2–88.4, and 488.4 mmol/l,
respectively).
In the losartan and enalapril groups, respectively, the LS
mean changes from baseline to 36 months in SBP were
increases of 4.6 and 1.5mmHg, and in DBP were increases of
2.9 and 0.4mmHg (Figure 4).
DISCUSSION
We report the results of a randomized open-label, 3-year
safety extension study of the first large, randomized,
controlled, double-blind study to demonstrate the anti-
proteinuric effect of a RAS agent losartan, in hypertensive
and normotensive children aged 1–17 years with proteinuria
of a wide range of etiologies. After 3 years, the LS mean
reduction from baseline in UPr/Cr was 30.0% for losartan
compared with 40.5% for enalapril (GMR: 1.2; 95% CI: 0.9,
1.6). Similar reductions in proteinuria were observed between
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Table 2 | Summary of AE, n (%)
Losartan,
N=134
Enalapril,
N=134
Any clinical AE 110 (82.1) 101 (75.4)
Any drug-relateda clinical AE 8 (6.0) 15 (11.2)
Any serious clinical AE 26 (19.4) 25 (18.7)
Any serious drug-relateda clinical AE 2 (1.5) 0 (0.0)
Died 3 (2.2) 3 (2.2)
Discontinuation of study medicationb
Due to clinical AE 10 (7.5) 8 (6.0)
Due to clinical drug-relateda AE 2 (1.5) 3 (2.2)
Due to a serious clinical AE 5 (3.7) 4 (3.0)
Due to a serious drug-relateda clinical AE 1 (0.7) 0 (0.0)
Any laboratory AE 22 (16.4) 19 (14.2)
Any drug-relateda laboratory AE 5 (3.7) 2 (1.5)
Any serious laboratory AE 1 (0.7) 0 (0.0)
Any serious drug-relateda laboratory AE 0 (0.0) 0 (0.0)
Discontinuation of study medication
Due to laboratory AE 1 (0.7) 0 (0.0)
Due to drug-relateda laboratory AE 1 (0.7) 0 (0.0)
Due to a serious laboratory AE 0 (0.0) 0 (0.0)
Due to a serious drug-relateda
laboratory AE
0 (0.0) 0 (0.0)
AEs of special interest
Renal dysfunctionc 11 (8.2) 9 (6.7)
Hyperkalemia 4 (3.0) 9 (6.7)
Hypotension 4 (3.0) 0 (0.0)
Angioedema 0 (0.0) 0 (0.0)
Abbreviation: AE, adverse event.
aDetermined by the investigator to be related to the drug.
bStudy medication withdrawn.
cIncludes renal disorder, renal failure, acute renal failure, and renal impairment.
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hypertensive and normotensive patients. A sensitivity analysis
adjusting for time-varying changes in BP showed that
changes in proteinuria in both treatment groups were
consistent with those observed in the main analysis. As
NSAIDs, systemic corticosteroids, and immunosuppressants
may produce substantial effects on proteinuria, a further
sensitivity analysis performed by excluding data from
patients within 2 weeks of taking NSAIDs and after starting
systemic corticosteroids or other immunosuppressants if they
had taken these medications for at least 50% of their
remaining time in the study, the LS mean reduction from
baseline in UPr/Cr was 26.5% with losartan vs. 28.2% with
enalapril (GMR: 1.02; 95% CI: 0.78, 1.34). The slightly lower
point estimates of UPr/Cr reduction and 95% CIs relative to
the main analysis are also consistent with the expectation that
systemic corticosteroids and other immunosuppressants
further lowered proteinuria, but nonetheless indicate that
losartan and enalapril maintained the lower level of
proteinuria initially achieved in the base study.
ACE-Is and ARBs are commonly used to treat proteinuria,
the range of reduction observed being in the order of
B30–50% in children and adults.4,6–8,10,15 The magnitude of
proteinuria reduction observed in this open-label extension
study is consistent with published data; however, given that
the baseline UPr/Cr was defined as the last value in the 12-
week double-blind study, overall reduction will have been
greater in those 50% of patients who were receiving losartan
at baseline14 The observed decrease in proteinuria was
sustained over 36 months. These findings are discordant
with results from the ESCAPE trial, which reported
regression of proteinuria to baseline levels over the course
of 42 months (starting after 2 years) in both study arms.13 In
ESCAPE, the authors speculate that the observed regression
to baseline values in proteinuria may be related to several
factors, including aldosterone breakthrough, a compensatory
upregulation of intrarenal vasoactive mediators, or the
natural course of underlying kidney disorders. The potential
reasons for the disparate findings in our study compared with
ESCAPE are uncertain, but may be related to differences in
patient compliance with study medication (e.g., in our study,
B75% of patients took treatment for 430 months and
B80% for more than 27 months) or in the relative efficacies
of the drugs tested.
The LS mean change from baseline in eGFR was 3.3ml/
min per 1.73m2 in the losartan group vs. 7.0ml/min per
1.73m2 in the enalapril group (between-treatment difference
3.8ml/min per 1.73m2 (95% CI: 15.2, 7.6)), representing
no substantial change over the course of the study. The
change from baseline in eGFR following adjustment for time-
varying changes in BP was also similar to that of the main
analysis.14 As with proteinuria, an additional sensitivity
analysis excluding data from patients on NSAIDs, systemic
corticosteroids, or other immunosuppressants was performed
for change in eGFR, as such medications can also affect
eGFR; these results were similar to those of the main analysis.
ACE-Is and ARBs have been shown to improve renal
outcomes in adult diabetic and non-diabetic proteinuric
diseases, but evidence in the pediatric population is limited.14
In the ESCAPE study, annual reductions in eGFR were 1.1
and 2.5ml/min per 1.73m2 in those maintained with BP
o50th percentile and those maintained between the 50th and
90th percentiles, respectively.13 As in the ESCAPE study, the
etiologies of proteinuria in our study varied widely, but the
average baseline eGFR in the 12-week double-blind study was
substantially higher than that in ESCAPE (118 vs. 46ml/min
per 1.73m2, respectively). Thus, the observed lack of change
in eGFR, in contrast to the decline seen in ESCAPE, could be
explained by the lesser severity of CKD of the patients in our
study.13 Whereas the 12-week follow-up period in the
12-week double-blind study may not have been of sufficient
duration to observe a significant change in eGFR, it is notable
that no significant decrease in eGFR was observed over the
3-year course of the extension phase.
Losartan was generally well tolerated. No clinically
significant differences in AEs were observed between losartan
and enalapril or between the normotensive and hypertensive
patients. The overall incidences of renal dysfunction,
hypotension, and hyperkalemia were low and generally
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comparable between the treatment groups, although numeri-
cally more cases of hypotension and hyperkalemia were
reported on losartan and enalapril, respectively. Although
combination use of ACE-Is and ARB was discouraged in the
present study, in several cases, investigators determined that
dual RAS blockade was clinically indicated. Several events of
hypotension and renal dysfunctions (4/24 (16.6%)) occurred
in patients on dual RAS inhibition. It is uncertain from these
low numbers whether the incidences of hypotension and
renal dysfunction in children are comparable to those in
adults, for whom accumulating data indicate that dual RAS
blockade poses a significantly higher risk of such AEs.16–18
Consistent with prior experience with RAS agents,12
hyperkalemia was the most frequent drug-related AE.
Increases in serum potassium and serum creatinine were
common. At 36 months, LS mean SBP and DBP increased in
both groups; however, at virtually every time point, mean BP
percentile decreased in both groups, which is most likely
explained by the expected natural increase in BP in children
with increasing age and height. Neither losartan nor enalapril
appeared to have an adverse effect on growth, development,
or sexual maturation.
The results from this study are confounded by changes in
medical treatment over up to 3 years of observation as
patients were managed according to the standard of care by
investigators, including the use of additional medications
deemed clinically appropriate. For this reason, end points
were designated as exploratory and no formal testing was
performed. Another limitation is that, for pragmatic reasons,
BP was monitored during regular clinical visits rather than by
ambulatory 24-h BP monitoring or home BP monitoring,
which may be more reliable methods, especially in children.
Finally, the data on losartan and enalapril in this study can be
interpreted only relative to each other as there was no placebo
arm, and no similar studies have been performed evaluating
ARBs alone in the pediatric population. The ESCAPE study is
the only other large and long-term study in a proteinuric
pediatric population, and reported a generally comparable
AE profile for ramipril. In conclusion, this study provides
important, new, long-term efficacy and safety data on
losartan in children with proteinuric renal disease of various
etiologies, with or without hypertension. Losartan produced
sustained decreases in proteinuria, without any appreciable
change in eGFR over 3 years of follow-up, and was
comparable in terms of efficacy and safety to enalapril. No
new or unexpected AE trends were observed; AEs for both
losartan and enalapril were generally consistent with the
known AE profiles of the drugs.
MATERIALS AND METHODS
Study design and participants
The methodology for the 12-week, randomized, double-blind,
parallel-group, placebo- or amlodipine-controlled phase of the
study has been published previously.14 Briefly, male and female
children and adolescents with a documented history of proteinuria
associated with CKD of any etiology (mean UPr/Cr X34mg/mmol
from three first-morning spot urine collections at baseline), with or
without hypertension (systolic or diastolic BP above the 95th
percentile by the National High Blood Pressure Education Program
Working Group standards for the patient’s gender, age, and height,
or local standards, if required),19 were randomized 1:1 to losartan vs.
placebo (normotensive stratum) or amlodipine (hypertensive
stratum). Patients were required to have an eGFR X30ml/min
per 1.73m2 calculated by the Schwartz formula20 based on a plasma
creatinine value measured at the central laboratory and could not
have taken ACE-Is, ARBs, or antihypertensive agent(s) other than
study drug within 28 days of randomization. Antihypertensive
therapies, other than study medications, were not allowed during
the study. Children with renal transplants were excluded.
All patients who completed the 12-week double-blind treatment
phase (or discontinued early because of increased proteinuria) were
invited to participate in the open-label extension. A stratified
randomization was used. Patients were stratified based on assigned
treatment in the double-blind treatment phase and randomized in a 1:1
ratio to either losartan or enalapril treatment for the duration of the
open-label extension study. Separate randomization lists were generated
for each stratum (i.e., assigned treatment in the double-blind treatment
phase). Interactive voice response services were called to determine
whether the patient was to be randomized to open-label enalapril or
losartan. Patients who could not swallow tablets or who weighed
o25kg were given losartan or enalapril suspension. Dosing of study
medication was at the investigator’s discretion; however, it was
recommended that the maximum dose of losartan not exceed 50mg/
day (if weight was o50 kg) or 100mg/day (if X50 kg), and the
maximum dose of enalapril was generally not to exceed 40mg/day.
The duration of the extension varied according to the time of
enrollment and was prespecified to continue until 100 patients
completed 3 years of follow-up. At the investigator’s discretion,
patients had monthly clinic visits at months 1, 2, and 3 to assess UPr/
Cr, routine laboratory safety parameters, cystatin C, and vital signs.
For all patients, these parameters were assessed at month 6 and every
6 months thereafter until the last study visit. During the period when
clinic visits were every 6 months, patients were contacted by
telephone between visits (every 3 months) to ensure safety.
This study was conducted as Merck Losartan Protocol 326 and
registered on http://www.clinicaltrials.gov as NCT00568178 (see
study protocol; Supplementary Information online). The study was
conducted in accordance with principles of Good Clinical Practice
and was approved by the appropriate institutional review boards
and regulatory agencies. Informed consent was obtained from
parents or guardians. Patient assent (when feasible) was obtained as
required by local regulations.
Endpoints
The main efficacy variables of the open-label extension phase were
changes from baseline (last value obtained in the double-blind
phase) in UPr/Cr ratio and eGFR (based on Schwartz equation20)
after 3 years of treatment. Height measurements were obtained at
different time points, and eGFR was estimated based on the most
recent height measurement.
Adverse experience data were reported for all subjects over the
entire duration of their participation in the study. Safety was
assessed by physical examinations, vital signs measurements,
laboratory safety evaluations (serum chemistry, hematology), and
AE monitoring. Growth was monitored using a sponsor-supplied
stadiometer. Sexual development was monitored by assessing the
change from baseline in Tanner stages. AEs of special interest were
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investigator-reported renal dysfunction, angioedema, hyperkalemia,
and hypotension. PDLCs assessments included: (i) hemoglobin
415 gm/l, (ii) serum sodium 4 5.0mmol/l, (iii) serum creatinine
434 mmol/l, and (iv) serum potassium 4 0.5mmol/l.
Statistical analysis
Efficacy analyses were based on the full analysis set population.
Patient inclusion was dependent on the presence of a baseline
measurement, consumption of at least one study dose, and a post-
randomization measurement.
For UPr/Cr ratio, the natural logarithmic transformation was
used to normalize data. The change in UPr/Cr ratio (on the
logarithmic scale) was analyzed using a mixed model, with fixed-
effect terms for treatment, time, treatment by time interaction,
stratum (assigned treatment in double-blind phase), and baseline
UPr/Cr (on the logarithmic scale). A random effect for patient and
an unstructured variance–covariance were used. Geometric means
(GMs) and GM ratios (GMR obtained after antilog transformation
of the difference in LS means) with 95% CI at all time points were
presented. The change in eGFR was analyzed using a mixed model
with fixed-effect terms for treatment, time, treatment by time
interaction, stratum (assigned treatment in double-blind phase),
and baseline eGFR. A random effect for patient and an unstructured
variance–covariance were used. LS means and differences in LS
means (95% CI) at all time points were presented. Owing to the
exploratory nature of the analyses, only LS means and differences in
LS means (95% CI) at all time points are presented.
Safety analyses were based on the all-patients-as-treated popula-
tion. Only summary statistics were provided by treatment group for
AEs recorded during the extension. Counts and percentages were
provided for the overall incidence of clinical and laboratory AEs as
well as specific AEs. Listings of patients with serious AEs, and AEs
resulting in discontinuations were provided. Analyses of clinical AEs of
special interest and PDLCs of selected laboratory tests were performed
using summary statistics. Changes from baseline in DBP and SBP were
analyzed using a mixed model similar to the main end points.
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